Skip to content
A Green Sign – Lifestyle
Author:
InnoCare Pharma
InnoCare Announces First Healthy Volunteer Dosed in Clinical Trial of Novel VAV1 Degrader ICP-538 in China
March 15, 2026
InnoCare’s next-generation TRKi Zurletrectinib Receives Priority Review for the Treatment of Pediatric Patients with Solid Tumors in China
March 5, 2026
←
Previous Page
1
2